DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 50-684/S-051, S-052

Wyeth Pharmaceuticals
Attention: Kathryn B. Gray
Manager
P.O. Box 8299
Philadelphia, PA 19101-8299

Dear Ms. Gray:

Please refer to your supplemental new drug applications dated March 26, 2007 (S-051) and March 29, 2007 (S-052), received March 26, 2007 and March 30, 2007, respectively, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Zosyn® (piperacillin sodium/tazobactam sodium) individual vials (S-051) and bulk pharmacy packaging (S-052). These applications are subject to the exemption provisions contained in section 125(d)(2) of Title I of the FDA Modernization Act of 1997.

We acknowledge receipt of your submissions dated July 3, 2007.

These "Changes Being Effected" supplemental new drug applications provide for revisions to the **WARNINGS** and **PRECAUTIONS/Information for Patients** sections to include information on *Clostridium difficile associated disease* (CDAD).

We completed our review of these applications as amended. These application are approved, effective on the date of this letter, for use as recommended in the content of labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format submitted on March 26 and March 29, 2007.

We note that your July 3, 2007 submission includes final printed labeling (FPL) for your package insert. You are responsible for assuring that the wording in this printed labeling is identical to that of the approved content of labeling in the structured product labeling (SPL) format.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
5515 Security Lane
HFD-001, Suite 5100
Rockville, MD 20852

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Susmita Samanta, MD, Regulatory Project Manager, at (301) 796-0803.

Sincerely,

{See appended electronic signature page}

Katherine A. Laessig, M.D.
Deputy Director
Division of Anti-Infective and Ophthalmology Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

Enclosure: Labeling submitted on March 26 and March 29, 2007

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Kathrine Laessig
4/17/2008 11:43:05 AM